Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.84 |
| ▸ | JAK2 | O60674 | 11/20 | 0.84 |
| ▸ | JAK3 | P52333 | 8/20 | 0.84 |
| ▸ | JAK1 | P23458 | 8/20 | 0.84 |
| ▸ | TYK2 | P29597 | 4/20 | 0.84 |
| ▸ | RET | P07949 | 4/20 | 0.84 |
| ▸ | FLT3 | P36888 | 4/20 | 0.84 |
| ▸ | AXL | P30530 | 4/20 | 0.84 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.84 |
| ▸ | WEE1 | P30291 | 3/20 | 0.84 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.84 |
| ▸ | PLK4 | O00444 | 2/20 | 0.84 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.84 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.84 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.84 |
| ▸ | PAK4 | O96013 | 2/20 | 0.84 |
| ▸ | ABL1 | P00519 | 2/20 | 0.84 |
| ▸ | EGFR | P00533 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330039 | 0.93 | BRD4 (0.82) | BRD4JAK2JAK3JAK1TYK2 | |
| SCHEMBL20285974 | 0.92 | JAK2 (0.81) | BRD4JAK2JAK3JAK1TYK2 | |
| SCHEMBL28489539 | 0.92 | BRD4 (0.81) | BRD4JAK2JAK3JAK1TYK2 | |
| Fedratinib SCHEMBL263741 | 0.91 | BRD4 (1.00) | BRD4JAK2JAK3JAK1TYK2 | |
| Fedratinib SCHEMBL29351417 | 0.91 | BRD4 (1.00) | BRD4JAK2JAK3JAK1TYK2 | |
| SCHEMBL30381504 | 0.91 | JAK3 (0.79) | BRD4JAK2JAK3JAK1TYK2 | |
| SCHEMBL264158 | 0.91 | JAK3 (0.79) | BRD4JAK2JAK3JAK1TYK2 | |
| Fedratinib SCHEMBL2734027 | 0.90 | BRD4 (0.98) | BRD4JAK2JAK3JAK1TYK2 | |
| SCHEMBL13868200 | 0.90 | BRD4 (0.79) | BRD4JAK2JAK3JAK1TYK2 | |
| SCHEMBL29112228 | 0.90 | BRD4 (0.76) | BRD4JAK2JAK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10730860-B2 | Diaminopyrimidine benzenesulfone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-20190135790-A1 | DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160332993-A1 | DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160332993-A1 | DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015117053-A1 | DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332993-A1 | DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRPF3 | BRD4 2/4885JAK2 806/4885JAK3 2823/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | BRD4 205/4885JAK2 273/4885JAK3 480/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | BRD4 205/4885JAK2 273/4885JAK3 480/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | BRD4 205/4885JAK2 273/4885JAK3 480/4885 |
| US-20190135790-A1 | DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRPF3 | BRD4 2/4885JAK2 806/4885JAK3 2823/4885 |
| US-10730860-B2 | Diaminopyrimidine benzenesulfone derivatives and uses thereof | BRDT, BRD4, BRPF3 | BRD4 2/4885JAK2 806/4885JAK3 2823/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | BRD4 1/4885JAK2 471/4885JAK3 739/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | BRD4 205/4885JAK2 273/4885JAK3 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.